Positive data for Roche multiple sclerosis injection
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Submission based on results from pivotal phase III trial showing all primary endpoints met
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Longest survival follow-up ever reported for immunotherapy treatment in this setting
The demand in Africa for COVID-19 vaccines has declined
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Subscribe To Our Newsletter & Stay Updated